Pandemic-era NIH grants (FY2019-2024) covering coronavirus, gain-of-function research, mRNA vaccines, biosafety, and related funding flows. Metadata + abstracts from NIH RePORTER.
Get an AI answer drawn only from the NIH Pandemic-Era Grants documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
Dermot Patrick McGovern · CEDARS-SINAI MEDICAL CENTER · 2021 · $330,143 — The inflammatory bowel diseases (IBD), Crohn's disease (CD) and ulcerative colitis (UC), are significant causes of morbidity with recent estimates suggesting there are more than 3 million Americans with IBD with very significant financial burden to the US economy. The world is currently in the middl…
Vincent C Bond · MOREHOUSE SCHOOL OF MEDICINE · 2021 · $177,500 — Abstract: Diversity in the rates of progression and mortality of COVID-19 disease within infected African American (AAs) subgroups are clearly not just a function of the underlying health conditions that increase the rate of mortality for COVID -19 patients, such as hypertension, obesity and diabete…
Shelli Farhadian · YALE UNIVERSITY · 2021 · $61,789 — Project Summary The COVID-19 pandemic has rampantly affected the population of the world and created lasting effects on the economy, health and psyche of the global community. Although it shares similarities with SARS-CoV-1, the full extent of the pathophysiology caused by SARS-CoV-2 is unclear. In …
Connie Schmaljohn · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2021 · $1,042,606 — The IRF evaluated the disease progression after intranasal SARS-CoV-2 exposure in young (56 weeks old), aged (60week-old) wild-type (WT) golden Syrian hamsters, and adult (1422 weeks old) hamsters expressing the human ACE2 (hACE2) receptor. Disease was characterized by clinical observations along wi…
ROBERT L DANNER · CLINICAL CENTER · 2021 — Nitric oxide (NO): NO up-regulates TNFa production (J Immunol 1994; Blood 1997) through a cGMP-independent pathway (J Biol Chem 1997) utilizing NO-responsive Sp1 promoter binding sites (J Biol Chem 1999; J Biol Chem 2003). Dysfunctional eNOS upregulates TNFa (J Biol Chem 2000) through ROS and ERK1/…
Vincent Munster · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2021 · $342,006 — The research program of the Virus Ecology Unit (VEU) is focused at understanding the drivers of virus emergence. Upon the emergence of SARS-CoV-2 in 2019, the research we swiftly pivoted to SARS-CoV-2. We were the first was to establish ACE2 as the SARS-CoV-2 receptor and rapidly developed a non-h…
Leonid B. Margolis · EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT · 2021 · $2,104,621 — 1. Various factors are hypothesized to trigger persistent immune activation in HIV-1-infected individuals. Here, we used human ex-vivo lymphoid tissue to test several hypotheses: (i)Immune activation may be the result of pro-inflammatory effects of certain antiretroviral drugs themselves; (ii)HIV-1-…
Philippe Youkharibache · DIVISION OF BASIC SCIENCES - NCI · 2021 · $37,993 — A significant part of my recent research efforts is focused on studying self-association determinants of molecular systems as revealed by their structural symmetries at several levels: from proteins assemblies to their protein supersecondary structures constituents (protodomains) [Youkharibache 2019…
JAMES D WEST · VANDERBILT UNIVERSITY MEDICAL CENTER · 2021 · $662,881 — Project Summary: ACE2 shows tremendous promise in the treatment of pulmonary arterial hypertension (PAH). It corrects many of the molecular defects caused by the most common heritable cause of disease, BMPR2 mutation. It has reversed disease in a variety of animal models of PAH, including heritable,…
Hongpeng Jia · JOHNS HOPKINS UNIVERSITY · 2021 · $204,688 — Project title: New ACE2 activator and its prodrug as novel therapeutic reagents for inflammatory pulmonary diseases. Pneumonia and associated inflammatory lung diseases (ILD) are a leading cause of death among children and elderly worldwide and a significant source of morbidity and mortality among h…
MARK C CHAPPELL · WAKE FOREST UNIVERSITY HEALTH SCIENCES · 2021 · $774,719 — ABSTRACT Hypertension is the leading risk factor for cardiovascular disease, is highly prevalent with high lifetime cumulative incidence rates, and is the leading cause of death compared to any other risk factor. Premature birth is an emerging and important risk factor for hypertension and cardiovas…
Xuyi Yue · NEMOURS CHILDREN'S HOSPITAL, DELAWARE · 2021 · $213,000 — PROJECT SUMMARY The coronavirus disease2019 (COVID-19) pandemic is an ongoing global pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). New COVID-19 cases and COVID-19 related deaths continue to rise rapidly and no effective drugs or vaccines are currently available…
Sergiy Gychka · GEORGETOWN UNIVERSITY · 2021 · $177,800 — Summary/Abstract Currently the world is suffering from the pandemics of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that uses angiotensin-converting enzyme 2 (ACE2) as a receptor to enter host cells. Millions of people have been infect…
Kurt Jarnagin · SYNBAL, INC. · 2021 · $233,363 — Abstract Phase I/II Synbal and the La Jolla Institute for Immunology (LJI) are combining efforts to create breakthrough new tools for COVID-19 research to enhance research and drug development for COVID-19 disease. We aim to create a state-of-the-art set of humanized mouse strains susceptible to SAR…
Todd B Reynolds · UNIVERSITY OF TENNESSEE KNOXVILLE · 2021 · $495,114 — Candida albicans and related Candida spp. are responsible for ~400,000 invasive infections/year, which have an ~50% mortality rate. A crucial virulence trait of C. albicans, and other fungi, is the ability to diminish their detection by their hosts. The cell wall carbohydrate ß(1,3)-glucan is an imp…
Roman Pogranichniy · KANSAS STATE UNIVERSITY · 2021 · $225,000 — Project Summary SARS-CoV-2 is an enveloped, positive-sense RNA virus that is known to interact with the angiotensin- converting enzyme-2 (ACE2) receptor of several species, including humans, cats, dogs, minks, ferrets, deer, and others. Since its emergence in Wuhan, China in late 2019, SARS-CoV-2, t…
WEI WENG · INGENIOUS TARGETING LABORATORY, INC. · 2021 · $297,204 — With the initial wave of zoonotic transmission firmly established in the human population worldwide, severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) poses an eminent threat to individuals, health care systems and societies. Various degrees of disease severity (from asymptomatic …
ROBERTO G BACCALA · SAN DIEGO BIOMEDICAL RESEARCH INSTITUTE · 2021 · $423,965 — Project Summary COVID-19 caused by the novel coronavirus SARS-Cov-2 first emerged in December 2019 and was officially declared a pandemic by WHO in March 2020. During this time, COVID-19 has caused millions of cases and deaths across the world. While most cases are asymptomatic or present with mild …
Ping Wang · MICHIGAN STATE UNIVERSITY · 2021 · $430,375 — ABSTRACT The outbreak of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome (SARS) coronavirus 2 (SARS-CoV-2), has resulted in a global pandemic with significant morbidity and mortality. Despite widespread efforts, it's far from certain that an effective vaccine will be…
ANTHONY W ORVEDAHL · WASHINGTON UNIVERSITY · 2021 · $1,410,500 — PROJECT SUMMARY/ABSTRACT The host inflammatory response is a double-edged sword that must vigorously defend against pathogens, but also requires restraint to prevent unintended injury to the host. The Cytokine Storm Syndrome (CSS) represents a state of unbridled inflammation that can be triggered b…